Stangier J, Su C A
Department of Pharmacokinetics and Drug Metabolism, Boehringer Ingelheim Pharma KG, Birkendorfer Strasse, D-88397 Biberach an der Riss, Germany.
J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1347-54.
This open-label, crossover study was performed to establish if there is evidence for interaction between telmisartan, an angiotensin II antagonist, and amlodipine, a class II (dihydropyridine) calcium channel antagonist, on the basis of pharmacokinetics and safety. In a two-way crossover trial, 12 healthy Caucasian males were randomized to receive once daily for 9 days oral amlodipine 10 mg with or without oral telmisartan 120 mg. After a washout period of > or = 13 days, the subjects were switched to the other medication regimen. The geometric means of the primary pharmacokinetic parameters at steady state (day 9) for amlodipine when given alone were the following: maximum plasma concentration (Cmax) 17.7 ng/mL, area under the plasma concentration-time curve (AUC) 331 ng.h/mL, and renal clearance 39.5 mL/min, with 8% of the total amlodipine dose being excreted. When concomitant telmisartan was given, the respective values were 18.7 ng/mL, 352 ng.h/mL, and 43.0 mL/min, with 9.4% of the total amlodipine dose being excreted renally. The limits of the 90% confidence intervals (CIs) for the ratios of these steady-state parameters were 0.97 to 1.14 for Cmax and 0.98 to 1.16 for AUC; both were within the predefined reference range (0.8 to 1.25) for bioequivalence. The high intersubject variability in urinary amlodipine excretion resulted in bioequivalence not being demonstrated for renal clearance. Adverse effects were few, mild to moderate in intensity, and transient whether amlodipine was given alone or with telmisartan. Vital signs, except for blood pressure, and clinical laboratory values were unaffected by either medication. The findings of this study show that concomitant telmisartan and amlodipine may be administered as there is no clinically significant variation in primary pharmacokinetic parameters of amlodipine in the presence of telmisartan, and the safety of the combination is comparable to that of amlodipine alone.
本开放标签、交叉研究旨在基于药代动力学和安全性确定血管紧张素II拮抗剂替米沙坦与II类(二氢吡啶)钙通道拮抗剂氨氯地平之间是否存在相互作用的证据。在一项双向交叉试验中,12名健康的白人男性被随机分组,接受为期9天的每日一次口服氨氯地平10 mg,同时服用或不服用口服替米沙坦120 mg。在洗脱期≥13天后,受试者换用另一种药物治疗方案。单独给予氨氯地平时,稳态(第9天)主要药代动力学参数的几何均值如下:最大血浆浓度(Cmax)17.7 ng/mL,血浆浓度-时间曲线下面积(AUC)331 ng·h/mL,肾清除率39.5 mL/min,总氨氯地平剂量的8%经肾排泄。当同时给予替米沙坦时,相应的值分别为18.7 ng/mL、352 ng·h/mL和43.0 mL/min,总氨氯地平剂量的9.4%经肾排泄。这些稳态参数比值的90%置信区间(CI)范围为:Cmax为0.97至1.14,AUC为0.98至1.16;两者均在生物等效性的预定义参考范围(0.8至1.25)内。氨氯地平尿排泄的受试者间高变异性导致肾清除率未显示生物等效性。不良反应较少,强度为轻至中度,且无论氨氯地平单独使用还是与替米沙坦合用均为短暂性。除血压外,生命体征和临床实验室值均不受任何一种药物的影响。本研究结果表明,替米沙坦和氨氯地平可以联合使用,因为在有替米沙坦存在的情况下,氨氯地平的主要药代动力学参数无临床显著差异,且联合用药的安全性与氨氯地平单独使用时相当。